CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Genetic Testing for Mitochondrial Disorders

Defines medical necessity criteria, covered CPT codes, and prior authorization requirements for genetic testing to diagnose mitochondrial disorders for Medicare Advantage Plans and Commercial Products of BCBSRI. Covers targeted familial variant testing, multi-gene nuclear panels, whole mitochondrial genome sequencing, and deletion analysis.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Genetic Testing for Mitochondrial Disorders

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2024

Next Review Date

Key ActionObtain prior authorization for Medicare Advantage Plans (required) and for Commercial Products (recommended); only the ordering physician may request authorization and must document medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material changes

4Covered CPT codes listed

>=100Minimum genes for nuclear panel

335Genes analyzed by Genomic Unity (0417U)

Coverage summary

Scope: Defines medical necessity criteria, covered CPT codes, and prior authorization requirements for genetic testing to diagnose mitochondrial disorders for Medicare Advantage Plans and Commercial Products of BCBSRI. It covers targeted familial variant testing, multi-gene nuclear panels, whole mitochondrial genome sequencing, and deletion analysis.

Overview: This policy addresses genetic testing for mitochondrial disorders and is CURRENT. It lists covered CPT codes (including 0417U, 81440, 81460, 81465), specifies testing types (targeted variant testing, nuclear gene panels, whole mitochondrial genome sequencing, deletion analysis), and requires prior authorization for Medicare Advantage Plans and recommends it for Commercial Products. Effective date: 2024-01-01; policy last reviewed 2023-09-06.

Medical necessity criteria

Medical Necessity for Diagnostic Genetic Testing

Genetic testing to establish a genetic diagnosis of a mitochondrial disorder may be considered medically necessary when ALL of the following are met:

ALL of the following

The individual has signs and symptoms of a mitochondrial disorder
Genetic testing is expected to establish a genetic diagnosis and may eliminate the need for muscle biopsy

Covered tests when criteria met

Targeted Familial Variant Testing (Preconceptional / At-risk relatives)

Targeted genetic testing for a known familial variant may be considered medically necessary under ALL of the following for Medicare Advantage Plans and Commercial Products:

ALL of the following

A variant that is known to be pathogenic for that specific mitochondrial disorder has been identified in the index case
There is a defined mitochondrial disorder in the family of sufficient severity to cause impairment of quality of life or functional status

Authorization

Codes

Covered CPT for Medicare Advantage and Commercial when criteria metCPTCovered

0417U	Genomic Unity Comprehensive Mitochondrial Disorders Analysis (whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes) - New Code Effective 10/01/2023
81440	Nuclear encoded mitochondrial genes panel, genomic sequence analysis of at least 100 genes (examples listed in policy)
81460	Whole mitochondrial genome genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection
81465	Whole mitochondrial genome large deletion analysis panel, including heteroplasmy detection if performed

Prior authorization and documentation

Prior Authorization

Prior authorization required for Medicare Advantage

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products for genetic testing for mitochondrial disorders. This applies to Medicare Advantage (required) and is recommended for Commercial plans.

Documentation Required

Ordering physician must obtain authorization and document medical necessity

Only the ordering physician may be involved in the authorization or appeal process; laboratories or third parties may not obtain authorization on behalf of the ordering physician. If a laboratory provides a service without authorization, that service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

Labs or third parties may not obtain authorization or participate in the authorization/appeal process for the ordering physician; unauthorized services billed by labs will be denied to the lab.

Background and evidence

Background: Mitochondrial diseases are multisystem disorders caused by pathogenic variants in mitochondrial DNA (mtDNA) or numerous nuclear-encoded mitochondrial genes; organs with high energy requirements are often affected. Because cells contain many copies of mtDNA, the proportion of variant to wild-type mtDNA (heteroplasmy) — expressed as a percentage from 0% to 100% — influences clinical expression and symptom thresholds. Genetic testing options include targeted familial variant testing, multi-gene nuclear panels, whole mitochondrial genome sequencing with heteroplasmy detection, and large deletion analysis. Genetic testing can confirm diagnosis, and in symptomatic patients a positive genetic result may eliminate the need for an invasive muscle biopsy.

Operational thresholds

Confidence: Confidence in this brief is 0.87. Notes: interpretation is based on the provided policy text; some formatting and typographical errors in the source were corrected to clarify meaning for operational use (for example, listing of CPT codes, gene-count thresholds, and authorization requirements).